Dishman Pharma completes US FDA inspection for Eprosartan Mesylate

Mumbai, May 05 (UNI) Dishman Pharmaceuticals&Chemicals Ltd has successfully completed US Food and Drug Administration (FDA) inspection for its facility located at, Bavla,a 100 per cent export oriented unit (EOU), to manufacture Eprosartan Mesylate, an anti hyper-tension drug, to be supplied to Solvay Pharmaceuticals, BV, a fortune 500 company.

Announcing this, the company said it is one of the two companies in the world with whom Solvay has entered into a long-term agreement for supply of newly developed molecule, whose patent is to expire in 2013.

Solvay will source its requirements for US markets from the company. It has increased the quantity of Eprosartan Mesylate to be supplied by the company to 50 per cent.

Eprosartan Mesylate is produced from three starting materials, whose process technology was developed by the company at it R&D, and Solvay has entered into long-term agreement to procure these starting materials to manufacture Eprosartan Mesylate by the second supplier from whom it is outsourcing its balance requirement of the drug.

UNI SN PP VKG1659